Consolidated Statements of Operations - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Jul. 31, 2017	Jul. 31, 2016
Revenues
Royalty and licensing revenue	$ 11,696,676	$ 18,406,142	$ 5,097,595
Treatment investment revenue	65,641	39,854	4,800,000
Total Revenue	11,762,317	18,445,996	9,897,595
Operating expenses
General and administrative	5,887,135	6,530,533	14,509,400
Research and development	2,486,514	3,171,599	2,808,757
Royalty expenses	1,408,012	0	0
Selling expenses	438,625	1,651,099	317,917
Total operating expenses	10,220,286	11,353,231	17,636,074
Income (loss) from operations	1,542,031	7,092,765	(7,738,479)
Other income (expense)
Interest income (expense), net	10,401	19,966	(11,890)
Gain (loss) on foreign exchange	10,027	18,356	(63,887)
Loss on settlement of liability	(13,917)	0	0
Total other income (expense)	6,511	38,322	(75,777)
Income (loss) before provision for income taxes	1,548,542	7,131,087	(7,814,256)
Provision for income taxes	(169,163)	(550,474)	0
Net income (loss)	$ 1,379,379	$ 6,580,613	$ (7,814,256)
Income (loss) per share of common stock:
Basic (in shares)	$ 0.66	$ 3.27	$ (4.09)
Diluted (in shares)	$ 0.31	$ 2.94	$ (4.09)
Weighted average common stock outstanding
Basic (in dollars per share)	2,077,663	2,014,540	1,910,489
Diluted (in dollars per share)	4,393,138	2,235,851	1,910,489